Progress in medicinal chemistry

by Lawton, G. Witty, D. R.

Type Book

Rate 0.0 /5

Details

Files

Reviews

Download

Title Statements

Full title :Progress in medicinal chemistry. / editors, G. Lawton, D.R. Witty.

Edition Statements

Publication Date:2016.
Edition:First edition

Publication Statements

Publisher(s):Elsevier
Place of Publication:Amsterdam
Language:eng
Publication Date:2016.

The Physical Object

Description:1 online resource (x, 249 pages) : : illustrations (some color)

Edition Identifiers

ISBN:9780444637420, 0444637427
oclc:ocn939528407
LC Classification:RS403
Dewey Decimal:615.19

2.3.1. Highly Polar, Non-absorbed Compounds2.3.1.1. Ileal Bile Acid Transporter Inhibitors; 2.3.1.2. Acarbose; 2.3.1.3. Larazotide; 2.3.1.4. Inhibitors of Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel; 2.3.2. High Lipophilicity, Low Solubility Drugs; 2.3.2.1. Pancreatic-Gastric Lipase Inhibitors; 2.3.2.2. Diacylglycerol Acyltransferase Inhibitors; 2.3.2.3. High Lipophilicity MTP Inhibitors; 2.3.2.4. Cholecystokinin-1 Receptor (CCK1R) Agonists; 2.3.2.5. Farnesoid X Receptor Agonist Fexaramine; 2.3.2.6. Colorectal Cancer Chemopreventives

2.3.2.7. Poorly Water-Soluble Antibacterials2.3.3. High MW ""Small"" Molecules; 2.3.3.1. From Ezetimibe to Canosimibe; 2.3.3.2. Intestinal Takeda G-Protein-Coupled Receptor 5 Agonist; 2.3.3.3. Tenapanor; 3. Rectally Administered Non-systemic Intestinal Drugs; 3.1. Tacrolimus; 3.2. Cyclosporine; 4. Conclusions; Acknowledgement; References; Chapter Two: Measurement, Interpretation and Use of Free Ligand Solution Conformations in Drug Discovery; 1. Introduction; 2. Measurement of Free Ligand Solution Conformational Preferences; 2.1. Solution NMR

2.2. The Blundell et al. [9] Solution NMR Approach3. Effectors Determining Free Lig…

Subjects